FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2327262010> ?p ?o ?g. }

• W2327262010 endingPage "799" @default.
• W2327262010 startingPage "799" @default.
• W2327262010 abstract "Nitric oxide (NO) plays a critical role in skeletal muscle function, including control of blood flow and muscle repair. In muscular dystrophies, synthesis of NO in the skeletal muscle is known to be defective therefore contributing to damage progression. In the present study, we evaluated the effects of naproxcinod, an NO-donating anti-inflammatory compound, in two models of muscular dystrophy, the alpha-sarcoglycan (alpha-SG) null mice, a model for limb-girdle muscle dystrophy, and the mdx mouse model for Duchenne muscle dystrophy (DMD). Naproxcinod (10 and 30 mg/kg/day) was orally administered for 7 months to mdx mice and for 4 months to alpha-SG null mice starting at 4 weeks of age. Muscle function was assessed by treadmill test at 4 months (both mdx and alpha-SG null mice) and 7 months of treatment (mdx mice). Serum creatine kinase (CK) was measured as index of skeletal muscle damage. Inflammatory infiltrates, as well as muscle regeneration were studied in diaphragm and tibialis anterior muscles. In mdx mice 30 mg/kg/day of naproxcinod significantly improved muscle function in terms of resistance to exercise with a recovery score of 12%; significantly reduced skeletal muscle inflammation and serum CK activity; and increased muscle regeneration. Likewise in alpha-SG null mice, 4 months of naproxcinod treatment led to a significant improvement of resistance to fatigue (recovery score of 59%), and to reduction of muscle inflammation and damage. Furthermore, both diaphragm and tibialis anterior muscles appeared fully regenerated, thus supporting the marked beneficial effects observed for muscle function. The results demonstrate that naproxcinod, through NO donation together with anti-inflammatory activity, produces significant and persistent therapeutic effects improving muscle function, reducing muscle inflammation and maintaining regeneration capacity of the muscle in two models of muscular dystrophies. Nitric oxide (NO) plays a critical role in skeletal muscle function, including control of blood flow and muscle repair. In muscular dystrophies, synthesis of NO in the skeletal muscle is known to be defective therefore contributing to damage progression. In the present study, we evaluated the effects of naproxcinod, an NO-donating anti-inflammatory compound, in two models of muscular dystrophy, the alpha-sarcoglycan (alpha-SG) null mice, a model for limb-girdle muscle dystrophy, and the mdx mouse model for Duchenne muscle dystrophy (DMD). Naproxcinod (10 and 30 mg/kg/day) was orally administered for 7 months to mdx mice and for 4 months to alpha-SG null mice starting at 4 weeks of age. Muscle function was assessed by treadmill test at 4 months (both mdx and alpha-SG null mice) and 7 months of treatment (mdx mice). Serum creatine kinase (CK) was measured as index of skeletal muscle damage. Inflammatory infiltrates, as well as muscle regeneration were studied in diaphragm and tibialis anterior muscles. In mdx mice 30 mg/kg/day of naproxcinod significantly improved muscle function in terms of resistance to exercise with a recovery score of 12%; significantly reduced skeletal muscle inflammation and serum CK activity; and increased muscle regeneration. Likewise in alpha-SG null mice, 4 months of naproxcinod treatment led to a significant improvement of resistance to fatigue (recovery score of 59%), and to reduction of muscle inflammation and damage. Furthermore, both diaphragm and tibialis anterior muscles appeared fully regenerated, thus supporting the marked beneficial effects observed for muscle function. The results demonstrate that naproxcinod, through NO donation together with anti-inflammatory activity, produces significant and persistent therapeutic effects improving muscle function, reducing muscle inflammation and maintaining regeneration capacity of the muscle in two models of muscular dystrophies." @default.
• W2327262010 created "2016-06-24" @default.
• W2327262010 creator A5000350455 @default.
• W2327262010 creator A5007995825 @default.
• W2327262010 creator A5010848776 @default.
• W2327262010 creator A5043885870 @default.
• W2327262010 creator A5052576774 @default.
• W2327262010 date "2013-10-01" @default.
• W2327262010 modified "2023-09-23" @default.
• W2327262010 title "P.11.2 Naproxcinod, a nitric oxide-donating anti-inflammatory compound, is effective in two mouse models of muscle dystrophy" @default.
• W2327262010 doi "https://doi.org/10.1016/j.nmd.2013.06.563" @default.
• W2327262010 hasPublicationYear "2013" @default.
• W2327262010 type Work @default.
• W2327262010 sameAs 2327262010 @default.
• W2327262010 citedByCount "0" @default.
• W2327262010 crossrefType "journal-article" @default.
• W2327262010 hasAuthorship W2327262010A5000350455 @default.
• W2327262010 hasAuthorship W2327262010A5007995825 @default.
• W2327262010 hasAuthorship W2327262010A5010848776 @default.
• W2327262010 hasAuthorship W2327262010A5043885870 @default.
• W2327262010 hasAuthorship W2327262010A5052576774 @default.
• W2327262010 hasConcept C121332964 @default.
• W2327262010 hasConcept C126322002 @default.
• W2327262010 hasConcept C134018914 @default.
• W2327262010 hasConcept C142724271 @default.
• W2327262010 hasConcept C157138929 @default.
• W2327262010 hasConcept C164292776 @default.
• W2327262010 hasConcept C24890656 @default.
• W2327262010 hasConcept C2776379899 @default.
• W2327262010 hasConcept C2776914184 @default.
• W2327262010 hasConcept C2777017193 @default.
• W2327262010 hasConcept C2778750056 @default.
• W2327262010 hasConcept C2778943923 @default.
• W2327262010 hasConcept C2779030066 @default.
• W2327262010 hasConcept C2779959927 @default.
• W2327262010 hasConcept C2780394045 @default.
• W2327262010 hasConcept C36880943 @default.
• W2327262010 hasConcept C519581460 @default.
• W2327262010 hasConcept C71924100 @default.
• W2327262010 hasConceptScore W2327262010C121332964 @default.
• W2327262010 hasConceptScore W2327262010C126322002 @default.
• W2327262010 hasConceptScore W2327262010C134018914 @default.
• W2327262010 hasConceptScore W2327262010C142724271 @default.
• W2327262010 hasConceptScore W2327262010C157138929 @default.
• W2327262010 hasConceptScore W2327262010C164292776 @default.
• W2327262010 hasConceptScore W2327262010C24890656 @default.
• W2327262010 hasConceptScore W2327262010C2776379899 @default.
• W2327262010 hasConceptScore W2327262010C2776914184 @default.
• W2327262010 hasConceptScore W2327262010C2777017193 @default.
• W2327262010 hasConceptScore W2327262010C2778750056 @default.
• W2327262010 hasConceptScore W2327262010C2778943923 @default.
• W2327262010 hasConceptScore W2327262010C2779030066 @default.
• W2327262010 hasConceptScore W2327262010C2779959927 @default.
• W2327262010 hasConceptScore W2327262010C2780394045 @default.
• W2327262010 hasConceptScore W2327262010C36880943 @default.
• W2327262010 hasConceptScore W2327262010C519581460 @default.
• W2327262010 hasConceptScore W2327262010C71924100 @default.
• W2327262010 hasIssue "9-10" @default.
• W2327262010 hasLocation W23272620101 @default.
• W2327262010 hasOpenAccess W2327262010 @default.
• W2327262010 hasPrimaryLocation W23272620101 @default.
• W2327262010 hasRelatedWork W197168872 @default.
• W2327262010 hasRelatedWork W1980154285 @default.
• W2327262010 hasRelatedWork W2106034176 @default.
• W2327262010 hasRelatedWork W2123038957 @default.
• W2327262010 hasRelatedWork W2317633493 @default.
• W2327262010 hasRelatedWork W2327262010 @default.
• W2327262010 hasRelatedWork W2333133447 @default.
• W2327262010 hasRelatedWork W3001978981 @default.
• W2327262010 hasRelatedWork W4254217058 @default.
• W2327262010 hasRelatedWork W4286719432 @default.
• W2327262010 hasVolume "23" @default.
• W2327262010 isParatext "false" @default.
• W2327262010 isRetracted "false" @default.
• W2327262010 magId "2327262010" @default.
• W2327262010 workType "article" @default.